Biguanide antihyperglycemic medicine

Metformin

The US tablet label gives metformin's plasma elimination half-life as approximately 6.2 hours; the app lists 6 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Metformin after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

The US label for metformin hydrochloride tablets describes metformin as a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.1 The same label gives 1995 as the initial US approval year.1 A separate US label covers an oral solution supplied as 500 mg per 5 mL (100 mg/mL).2 The app files metformin under the category "supplement" and the sub-category "AMPK Activator", and grades its evidence as emerging.

The label states that metformin "decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization".1 In muscle biopsies from the MASTERS trial of adults aged 65 and older, the authors report that "Metformin led to an increase in AMPK signaling, and a trend for blunted increases in mTORC1 signaling in response to PRT" (progressive resistance exercise training).3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
60%
Typical dose
500–2000 mg/day
Route
Oral
Time to peak
~2.5 h

The table sets the app's figures beside what the US tablet label reports.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~6 hPlasma elimination half-life of approximately 6.2 hours and blood elimination half-life of approximately 17.6 hours on the US tablet label1
Bioavailability60%Absolute bioavailability of approximately 50% to 60% for a 500 mg tablet given under fasting conditions1
Time to peak~2.5 hLabel Table 4 mean Tmax of 2.75, 2.64 and 1.79 hours in healthy nondiabetic adults after 500 mg single, 850 mg single and 850 mg three times daily dosing (the label lists 3.32 and 2.01 hours in adults with type 2 diabetes for the 850 mg single and repeated doses)1
Steady stateNot in the appSteady state plasma concentrations reached within 24 to 48 hours at usual clinical doses and schedules1

Food lowered the extent of absorption: after a single 850 mg tablet with food, the label reports about a 40% lower mean peak plasma concentration, a 25% lower area under the curve and a 35-minute longer time to peak than the same tablet fasting.1 The label states that metformin is excreted unchanged in the urine, with no metabolites identified in humans and no hepatic metabolism, and that about 90% of the absorbed drug is eliminated by the renal route within the first 24 hours.1 It adds that in decreased renal function the plasma and blood half-life of metformin is prolonged.1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: twice a day (label starting schedule)1, once a day (label starting schedule, 850 mg)1.

An illustration from a pharmacokinetic model using a half-life of 6 hours. It is not a measured level or a suggested dose.

Strength converter

US oral solution label strength: 100 mg per mL2

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
US tablet label trial, 29 weeks1Double-blind, placebo-controlled, multicenter US trial; sponsor not stated in the label textObese patients with type 2 diabetes whose hyperglycemia was not adequately controlled with diet alone (baseline FPG about 240 mg/dL); 141 on metformin, 145 on placeboMetformin up to 2550 mg/day or placebo for 29 weeksFasting plasma glucose changed by –53.0 mg/dL on metformin and 6.3 on placebo; HbA1c by –1.4 and 0.4 points (both p-values 0.001); diarrhea in 53% against 12%1
UKPDS Group, UKPDS 34, Lancet 19984Randomised controlled trial of an intensive policy with metformin against a conventional policy, median 10.7 years; secondary comparison with other intensive therapies; supplementary trial753 overweight patients (mean age 53 years) with newly diagnosed type 2 diabetes in the main trial: 342 metformin, 411 conventional; 537 in the supplementary trialMetformin aiming for fasting plasma glucose below 6 mmol/L against a conventional policy, primarily with diet alone; dose not given in the PubMed recordRisk reductions of 32% for any diabetes-related endpoint (95% CI 13-47, p=0.002), 42% for diabetes-related death and 36% for all-cause mortality; early addition of metformin to sulphonylurea was associated with a 96% increased risk of diabetes-related death4
Knowler and colleagues, DPP, New England Journal of Medicine 20025Randomised, placebo-controlled with a lifestyle arm; NIH-supported, with Bristol-Myers Squibb and Parke-Davis among the supporters3234 nondiabetic persons with elevated fasting and post-load glucose; mean age 51 years, mean BMI 34.0Metformin 850 mg twice daily, placebo, or lifestyle program; average follow-up 2.8 yearsDiabetes incidence 11.0 (placebo), 7.8 (metformin) and 4.8 (lifestyle) per 100 person-years; metformin reduced incidence by 31% (95% CI 17 to 43) against placebo and lifestyle by 58%5
Walton and colleagues, MASTERS, Aging Cell 20193Randomised, double-blind, placebo-controlled, multicenter; NIH-funded94 healthy women and men aged 65 and older (metformin N = 46, placebo N = 48)Metformin 1,700 mg/day or placebo with 14 weeks of supervised resistance trainingPlacebo gained more lean body mass (p = .003) and thigh muscle mass than metformin; strength gains showed a trend toward being blunted that did not reach statistical significance3
Konopka and colleagues, Aging Cell 20196Randomised, double-blind, placebo-controlled; grants from Dairy Management Inc and Dexcom, Inc among othersOlder adults (62 ± 1 years) free of chronic disease with a type 2 diabetes risk factor; placebo n = 26, metformin n = 27Metformin or placebo during 12 weeks of aerobic exercise training; titrated to 2,000 mg/day in the metformin groupMetformin attenuated the increase in whole-body insulin sensitivity and VO2 max after training, and abrogated the exercise-mediated increase in muscle mitochondrial respiration; the VO2max attenuation of about 50% had p = 0.086
Aroda and colleagues, DPP and DPPOS, Journal of Clinical Endocrinology and Metabolism 20167Secondary analysis of a randomised trial and its outcomes study; NIDDK-funded, with Bristol-Myers Squibb and Parke-Davis support during the DPPAnalytic population with stored samples: 857 placebo and 858 metformin at 5 years; 756 and 764 at 13 yearsMetformin 850 mg twice daily or placebo for 3.2 years, then open-label metformin for an additional 9 yearsLow B12 in 4.3% on metformin against 2.3% on placebo at 5 years (P = .02) and 7.4% against 5.4% at 13 years (P = .12); low or borderline-low B12 in 19.1% against 9.5% at 5 years and 20.3% against 15.6% at 13 years (P = .02)7
de Jager and colleagues, HOME trial, BMJ 20108Multicentre randomised placebo-controlled trial; supported by Altana, Lifescan, Merck Santé, Merck Sharp & Dohme and Novo Nordisk390 patients with type 2 diabetes receiving insulin, in three Dutch non-academic hospitalsMetformin 850 mg or placebo three times a day for 4.3 yearsMean vitamin B-12 concentration lower by 19% (95% CI 24% to 14%) than placebo; absolute risk of B-12 below 150 pmol/l 7.2 percentage points higher (95% CI 2.3 to 12.1)8

Deeper analysis: UKPDS 34

The UK Prospective Diabetes Study Group reported UKPDS 34 in The Lancet in 1998.4 Of 4075 patients recruited at 15 centres, 1704 overweight patients with newly diagnosed type 2 diabetes (mean age 53 years) had raised fasting plasma glucose after 3 months' diet, and 753 of them entered the randomised comparison of conventional policy, primarily diet alone (n=411), against intensive control with metformin (n=342).4 The primary outcome measures were aggregates of any diabetes-related clinical endpoint, diabetes-related death and all-cause mortality.4 Median HbA1c was 7.4% on metformin and 8.0% in the conventional group, with risk reductions of 32% for any diabetes-related endpoint, 42% for diabetes-related death (9-63, p=0.017) and 36% for all-cause mortality (9-55, p=0.011).4 The supplementary randomised trial of 537 patients already on maximum sulphonylurea therapy reported a different direction: early addition of metformin was associated with a 96% increased risk of diabetes-related death (95% CI 2-275, p=0.039) compared with continued sulphonylurea alone.4 The authors' interpretation is that metformin "may be the first-line pharmacological therapy of choice in these patients", with less weight gain and fewer hypoglycaemic attacks than insulin and sulphonylureas.4 The PubMed record lists the publication types "Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.", but names no sponsor or author ties, and only that record's summary was read, so the authors' stated limitations are not reported here.4

Deeper analysis: Diabetes Prevention Program

Knowler and colleagues, for the Diabetes Prevention Program Research Group, reported the trial in the New England Journal of Medicine in 2002.5 The authors randomly assigned 3234 persons to metformin 850 mg twice daily, placebo or a lifestyle program, with metformin started at 850 mg once a day and raised at one month unless gastrointestinal symptoms warranted a longer titration.5 The mean age was 51 years and the mean body-mass index 34.0.5 Average follow-up was 2.8 years, and the diabetes incidence per 100 person-years was 11.0 on placebo, 7.8 on metformin and 4.8 with lifestyle.5 Metformin reduced incidence by 31 percent (95 percent confidence interval, 17 to 43 percent) and lifestyle by 58 percent (48 to 66 percent) against placebo, and the authors state that "the lifestyle intervention was significantly more effective than metformin".5 Gastrointestinal symptoms (diarrhea, flatulence, nausea and vomiting) occurred at 77.8 events per 100 person-years on metformin against 30.7 on placebo, and the paper states that hospitalization and mortality rates were unrelated to treatment and that no deaths were attributed to the study intervention.5 The authors note that placebo-group incidence "was higher than we had anticipated" and that whether results would be similar with an isolated elevation of fasting or post-load glucose "is likely but unknown".5 The funding statement lists the National Institutes of Health institutes, the Indian Health Service, the Centers for Disease Control and Prevention, the American Diabetes Association, Bristol-Myers Squibb and Parke-Davis; the acknowledgments thank Lipha Pharmaceuticals "for the metformin and placebo", and a footnote states that one author owns stock in Bristol-Myers Squibb, "which sells metformin in the United States".5

Deeper analysis: MASTERS resistance training trial

Walton and colleagues, from the Center for Muscle Biology at the University of Kentucky and collaborating sites, reported the MASTERS trial in Aging Cell in 2019 (ClinicalTrials.gov NCT02308228).3 Participants received 1,700 mg/day metformin (N = 46) or placebo (N = 48), and all performed 14 weeks of supervised training; all analyses were on the analytic sample (N = 94).3 Placebo gained more lean body mass (p = .003) and thigh muscle mass (p less than .001) than metformin, and increases in CT thigh muscle area (p = .005) and density (p = .020) were greater on placebo.3 The null and secondary results were that strength gains showed a trend toward being blunted that "did not reach statistical significance", metformin "did not affect fiber hypertrophy", weight loss, or improvements in fasting glucose, glucose tolerance and insulin sensitivity.3 The metformin group reported more gastrointestinal side effects, which the authors state "did not result in discontinuation of drug and did not affect exercise adherence in our generally healthy senior population", and the paper reports that adverse events were more likely to occur with metformin (p = .002).3 The authors name one limitation: "it did not include sedentary control groups", so no conclusion can be drawn about metformin alone, and they add that "the majority of our cohort was nonobese and free from metabolic disease".3 The funding statement names the National Institute on Aging and the National Center for Advancing Translational Sciences, and the authors state they have "no conflict of interests to disclose".3

Deeper analysis: Konopka aerobic exercise trial

Konopka and colleagues reported a trial of metformin during aerobic exercise training in Aging Cell in 2019.6 In a double-blinded design, adults aged 62 ± 1 years were randomized to placebo (n = 26) or metformin (n = 27) during 12 weeks of aerobic exercise training (AET).6 All participants were free of chronic disease but had at least one risk factor for type 2 diabetes, and the dose was decreased from 2,000 to 1,500 mg/day in 11 participants with gastrointestinal discomfort (placebo n = 3; metformin n = 8).6 Metformin attenuated the increase in whole-body insulin sensitivity (p = 0.02) and abrogated the exercise-mediated increase in skeletal muscle mitochondrial respiration, while mitochondrial protein synthesis rates did not differ between treatments.6 The attenuation of the VO2max increase was about 50% but "did not reach statistical significance (p = 0.08)", and in the metformin group 58% of participants were positive responders for insulin sensitivity and 42% responded negatively.6 The authors state that "one potential limitation is that we did not include a metformin group alone" and that the study did not use a hyperinsulinemic-euglycemic clamp "as the gold standard approach of measuring peripheral insulin sensitivity".6 Their conclusion is that "additional studies are needed to understand the mechanisms that elicit positive and negative responses to metformin with and without exercise".6 The grants listed in the record include Dairy Management Inc and Dexcom, Inc alongside National Institutes of Health awards, and the authors state they "have no conflict of interests to disclose".6

Deeper analysis: vitamin B12 in the DPPOS and HOME trials

Aroda and colleagues (Diabetes Prevention Program Research Group) analysed vitamin B12 in a secondary analysis of the DPP and its outcomes study, and de Jager and colleagues reported the HOME randomised trial in the BMJ in 2010.7,8 In the DPPOS analysis, low B12 (203 pg/mL or less) occurred more often on metformin than placebo at 5 years (4.3% against 2.3%; P = .02) but not at 13 years (7.4% against 5.4%; P = .12), while combined low and borderline-low B12 was more common on metformin at both times.7 The authors report that anemia prevalence was higher on metformin but "did not differ by B12 status", and that neuropathy prevalence was higher on metformin with low B12 levels, although the number of cases was small.7 Their stated limitations include that "Stored serum samples from other time points, including DPP baseline, were not available" and that "information about the use of over-the-counter vitamin supplements was not collected during the study".7 The NIDDK funded the clinical centers, Bristol-Myers Squibb and Parke-Davis gave additional funding and material support during the DPP, Lipha (Merck-Santé) provided medication, and the authors report "no relevant conflicts of interest to disclose".7 In the HOME trial (390 patients with type 2 diabetes receiving insulin; 850 mg metformin or placebo three times a day for 4.3 years), metformin was associated with a mean decrease in vitamin B-12 of 19% (95% CI 24% to 14%) and in folate of 5% (95% CI 10% to 0.4%; P=0.033), with no significant effect of metformin on folate after adjustment for body mass index and smoking, and with a homocysteine increase of 5% (95% CI -1% to 11%; P=0.091).8 The absolute risk of vitamin B-12 below 150 pmol/l was 7.2 percentage points higher on metformin (95% CI 2.3 to 12.1).8 The HOME authors list as a limitation that "we measured only total vitamin B-12 levels and not levels of holotranscobalamin II or methylmalonic acid".8 The trial was supported by grants from Altana, Lifescan, Merck Santé, Merck Sharp & Dohme and Novo Nordisk, which the paper says "had no role in the design and conduct of the study"; the authors declare financial support for the submitted work from Merck Sharp & Dohme, and one author affiliation lists Merck Netherlands.8

5

Doses reported in studies and on labels

The app's typical dose is 500 to 2000 mg/day by the oral route; the table gives the schedules that the labels and studies report, each with its reference.

Table 5.1Doses reported in studies and on labels5 rows
Where reportedPeopleDose, route and scheduleDuration, n and comparatorReference
US tablet label, adult dosageAdults with type 2 diabetes mellitusOral; starting dose 500 mg twice a day or 850 mg once a day with meals; increments of 500 mg weekly or 850 mg every 2 weeks up to a maximum of 2550 mg per day in divided dosesLabel dosing; no comparator1
US tablet label, pediatric dosagePediatric patients 10 years of age and olderOral; starting dose 500 mg twice a day with meals; increments of 500 mg weekly up to a maximum of 2000 mg per day in divided doses twice dailyLabel dosing; no comparator1
US oral solution labelAdults and pediatric patients with type 2 diabetes mellitus per the solution labelOral solution, 500 mg per 5 mL (100 mg/mL)Label strength; no comparator2
DPP, 2002Nondiabetic adults at high risk of diabetesOral; 850 mg once a day, raised to 850 mg twice daily at one monthAverage follow-up 2.8 years; 3234 randomised across metformin, placebo and lifestyle arms5
MASTERS, 2019Healthy adults aged 65 and olderOral; 1,700 mg/day target dose14 weeks of resistance training; N = 46 metformin, N = 48 placebo3

The label's adult maximum of 2550 mg per day is higher than the app's upper typical dose of 2000 mg/day, which matches the label's pediatric maximum.1

6

Side effects reported

In the label's US trial (141 on metformin, 145 on placebo), diarrhea was reported by 53% of metformin-treated patients against 12% on placebo, and nausea or vomiting by 26% against 8%.1 The label lists the most common adverse reactions (over 5%) as diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort and headache, and states that diarrhea led to discontinuation in 6% of patients.1 The boxed warning states that "Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias".1 Its listed risk factors include renal impairment, age 65 years or greater, radiological studies with contrast, excessive alcohol intake and hepatic impairment.1 The label states that in 29-week trials a decrease to subnormal levels of previously normal serum vitamin B12 was observed in approximately 7% of patients, and that this may be associated with anemia but appears to be rapidly reversible with discontinuation of the drug or vitamin B12 supplementation.1 The label notes that metformin may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue.1 Postmarketing reports include "Cholestatic, hepatocellular, and mixed hepatocellular liver injury", which the label says come from voluntary reports from a population of uncertain size.1

7

Bloodwork and markers

The app lists HbA1c, fasting glucose, serum B12 and liver enzymes (ALT, AST) as markers to monitor. In the label's 29-week trial, the mean change in fasting plasma glucose at the final visit was –53.0 mg/dL on metformin against 6.3 on placebo, and HbA1c changed by –1.4 against 0.4 percentage points, with p-values of 0.001 for both.1 The label states: "Measure hematologic parameters on an annual basis and vitamin B" 12 "at 2 to 3 year intervals in patients on Metformin Hydrochloride and manage any abnormalities".1 For liver markers, the label's liver statements concern avoidance in hepatic impairment and postmarketing liver injury; the tablet label text does not mention ALT or AST by name.1

8

Regulatory and anti-doping status

The US tablet label gives an initial US approval year of 1995 and carries a boxed warning for lactic acidosis.1 The label states that "There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Metformin Hydrochloride Tablets".1 The WADA 2026 Prohibited List places metabolic modulators in class S4, "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and S4.4.1 covers activators of the AMP-activated protein kinase (AMPK), with the examples BAM15, AICAR and MOTS-c.9 The list text does not contain the word metformin, and it does not state whether metformin is treated as an AMPK activator under S4.4.1.9

9

Storage and handling

The US tablet label states: "Store at 20°to 25°C (68°to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)".1

The app's notes describe the TAME trial as ongoing; a ClinicalTrials.gov search for "Targeting Aging with Metformin TAME" on 16 November 2026 returned one record, the CALERIE Legacy Study (NCT05651620), so a TAME registry entry was not confirmed. The app's notes describe emerging use for longevity; Konopka and colleagues write that metformin "was also recently proposed as a potential therapy to slow aging", and the tablet label's stated indication is glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.6,1 The MASTERS authors state that "The effects of metformin in frail elderly, alone or in combination with resistance exercise, need further study".3

What is the half-life of metformin?

The US tablet label gives a plasma elimination half-life of approximately 6.2 hours, and the app lists 6 hours.1 The label gives approximately 17.6 hours in blood.1

What is the bioavailability of metformin?

The US tablet label gives an absolute bioavailability of approximately 50% to 60% for a 500 mg tablet under fasting conditions, and the app lists 60%.1 The label says food decreases the extent of absorption.1

How long does metformin take to reach its peak level?

The app lists about 2.5 hours, and the label's Table 4 gives mean Tmax values of 2.75, 2.64 and 1.79 hours in healthy nondiabetic adults.1

Is metformin banned by WADA?

The 2026 WADA Prohibited List text read does not contain the word metformin.9 The list prohibits activators of the AMP-activated protein kinase (AMPK) at all times, naming BAM15, AICAR and MOTS-c as examples, and does not state whether metformin is covered.9

Is metformin approved by the FDA?

The US tablet label gives an initial US approval year of 1995 for type 2 diabetes mellitus in adults and pediatric patients 10 years of age and older.1

Does metformin lower vitamin B12?

The US tablet label states that a decrease to subnormal levels of previously normal serum vitamin B12 was observed in approximately 7% of patients in 29-week trials.1 In the HOME trial of patients with type 2 diabetes on insulin, mean vitamin B-12 concentration was 19% lower on metformin than on placebo over 4.3 years (95% CI 24% to 14%).8

What are the most common side effects of metformin?

The US tablet label lists diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort and headache as adverse reactions in over 5% of treated patients.1

Does metformin affect exercise adaptations?

Two randomized trials in older adults reported smaller training responses on metformin than on placebo.3,6 In MASTERS the strength result did not reach statistical significance, and in the Konopka trial the VO2max attenuation of about 50% had p = 0.08.3,6

What is the boxed warning on metformin?

The boxed warning is for lactic acidosis, with postmarketing cases that "have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias".1

13

References

  1. Golden State Medical Supply, Inc. Metformin hydrochloride tablets. US prescribing information, DailyMed record version 14, 2026. DailyMed tablet label
  2. VistaPharm, LLC. Metformin hydrochloride oral solution. US prescribing information, DailyMed record version 10, 2026. DailyMed oral solution label
  3. Walton RG, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial. Aging Cell 2019. PMID 31557380
  4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998. PMID 9742977
  5. Knowler WC, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002. PMID 11832527
  6. Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell 2019. PMID 30548390
  7. Aroda VR, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016. PMID 26900641
  8. de Jager J, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010. PMID 20488910
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list